Evidence map›Paper›PMID 36255604›Full record

ReviewCurrent oncology reports2022

Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.

Prarthna V Bhardwaj, Yara G Abdou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Prarthna V BhardwajDivision of Hematology-Oncology, University of Massachusetts Chan School of Medicine - Baystate, Springfield, USA.
Yara G AbdouDivision of Oncology, University of North Carolina at Chapel Hill, 170 Manning Dr, Chapel Hill, NC, 27514, USA. Yara_Abdou@med.unc.edu.ORCID 0000-0002-4827-8613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewIn this article, we discuss recent advances in germline genetic testing for patients with breast cancer and highlight current limitations and impacts on clinical care. We also provide an update on the therapeutic implications of having a germline mutation, including targeted systemic therapy options for treating early and metastatic breast cancer. RECENT

findingsApproximately 5 to 10% of women diagnosed with breast cancer have a pathogenic variant in a hereditary cancer susceptibility gene, which has significant implications for managing these patients. Previously, testing was done mainly to inform screening and risk-reduction treatment; however, more recently, germline genetic results have significant systemic therapy implications that can meaningfully improve outcomes in breast cancer patients, especially with oral poly-ADP-ribose polymerase (PARP) inhibitors. These systemic therapy advances implore a shift in paradigm for whom to test moving forward and how to modify the existing testing models to meet the increasing demand for germline testing, which is expected to grow exponentially.

Indexed as

BRCA2 ProteinBreast NeoplasmsBRCA1 ProteinFemaleGenetic TestingGerm CellsHumansPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsBRCA1BRCA2Breast cancerGermline genetic testingOlaparibPARP inhibitorsSystemic therapyTargeted therapies

Identifiers

PMID36255604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.